

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC. NO.  
4-20937/A/PCV  
APPLICATION NO.  
09/214,371  
APPLICANT  
LANE ET AL.  
FILING DATE  
JANUARY 5, 1999

Sheet 1 of 2

RECEIVED

AUG 02 1999

TECH CENTER 1600  
Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
TJL	AA	5,362,623	11/8/94	Vogelstein et al.	435	6	3/31/92
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
TJL	AH	WO 96 02642	2/1/96				<input type="checkbox"/>	<input type="checkbox"/>
	AI	WO 93 20238	10/14/93				<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 95 07934	3/23/95				<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

TJL	AM	Ball K. et al., Current Biology, Vol. 7 (1), "Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 <sup>WAF1</sup> ", pp. 71-80 (1996)
TJL	AN	Blaydes J. et al., Oncogene, Vol. 14, "Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2," pp. 1859-1868 (1997)
TJL	AO	Blommers M.J.J. et al., J. Am. Chem. Soc., Vol. 119 (14), "On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2," pp. 3425-3426 (1997)
TJL	AP	Böttger A. et al., J. Mol. Biol., Vol. 269, "Molecular Characterization of the hdm2-p53 Interaction," pp. 744-756 (1997)
TJL	AQ	Böttger V. et al., Oncogene, Vol. 18, "Comparative study of the p53-mdm2 and p53-MDMX interfaces," pp. 189-199 (1999)
TJL	AR	Böttger V. et al., Oncogene, Vol. 13, "Identification of novel mdm2 binding peptides by phage display," pp. 2141-2147 (1996)

EXAMINER

DATE CONSIDERED


6/27/00

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOC. NO.  
 4-20937/A/PCV  
 APPLICATION NO.  
 09/214,371  
 APPLICANT  
 LANE ET AL.  
 FILING DATE  
 JANUARY 5, 1999

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<i>TL</i>	AA	Chorev M. and Goodman M., Acc. Chem. Res., Vol. 26, "A Dozen Years of Retro-Inverso Peptidomimetics," pp. 266-273 (1993)
<i>TL</i>	AB	Derossi D. et al., J. of Biol. Chem., Vol. 269 (14), "The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes," pp. 10444-10450 (1994)
<i>TL</i>	AC	Gannon J. et al., Oncogene, Vol. 9 (5), "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form," pp. 1595-1602 (1990)
<i>TL</i>	AD	Lane D., Exp. Opin. Ther. Patents, Vol. 6 (8), "Patent Evaluation - Oncologic, Endocrine & Metabolic - Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer," pp. 805-809 (1996)
<i>TL</i>	AE	Lee H. et al., J. Bacteriol., Vol. 173 (17), "Molecular Characterization of <i>nosA</i> , a <i>Pseudomonas stutzeri</i> Gene Encoding an Outer Membrane Protein Required to Make Copper-Containing N <sub>2</sub> O Reductase," pp. 5406-5413 (1991)
<i>TL</i>	AF	Lin J. et al., Genes & Devel., Vol. 8 (10), "Several hydrophobic amino acids in the p52 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein," pp. 1235-1246 (1994)
<i>TL</i>	AG	Lin Y-Z et al., J. of Biol. Chem., Vol. 270 (24), "Inhibition of Nuclear Translocation of Transcription Factor NF- $\kappa$ B by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence," pp. 14255-14258 (1995)
<i>TL</i>	AH	Momand J. et al., Cell, Vol. 69, "The <i>mdm-2</i> Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation," pp. 1237-1245 (1992)
<i>TL</i>	AI	Mundt M. et al., "The tumor suppressor p53 as a target for tumor therapy: An <i>In vitro</i> transcription system as an indicator of active p53," Abstract of presentation at University of Dundee, Dundee, Scotland, July 5-9, 1996.
<i>TL</i>	AJ	Olson D. et al., Oncogene, Vol. 8, "Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes," pp. 2353-2360 (1993)
<i>TL</i>	AK	Phelan J.C. et al., J. of Amer. Chem. Soc., Vol. 119 (3), "A General Method for Constraining Short Peptides to an $\alpha$ -Helical Conformation," pp. 455-460 (1997)
<i>TL</i>	AL	Picksley S. et al., Oncogene, Vol. 9, "Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides," pp. 2523-2529 (1994)
<i>TL</i>	AM	Picksley S. and Lane D., Current Opinion in Cell Biology, Vol. 6, "p53 and Rb: their cellular roles," pp. 853-858 (1994)
<i>TL</i>	AN	Wallace C., Current Opinion in Biotechnology, Vol. 6, "Peptide ligation and semisynthesis," pp. 403-410 (1995)

EXAMINER

*Thomas J. Lane*

DATE CONSIDERED

*6/27/00*

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.